#pharma regulatory consultants in Delhi

[ikrispharmaa]

Get Your Named Patient Medicine From Ikris Pharma Network

Today, one of the most common questions asked by the patients, caregivers, and doctors is “How are you able to provide access to approved medicines that aren’t approved in my native country?” Put simply, we use the Named Patient Import Program in india , through which patients can access approved and hard-to-access medicines that are currently unapproved or unavailable in their own country.

There are some hard-to-access medicines which have been approved recently in Europe, USA, Japan etc but not yet approved in India or any other countries. Also, some hard-to-access drugs are not allowed to be imported or marketed commercially in some countries. Though, they may be required to treat such patients who have exhausted all other existing and probable treatment options in their own country. As per Indian Drugs and Cosmetics Rules, 1945, the patient can import these hard-to-access medicines in a tiny proportions. Similar regulatory provisions are also available in other countries.

What is the Named Patient Import Program: In most places, any patient (the Named Patient) with a life-threatening, chronic or severely debilitating illness has the authority to access, buy, and import medicines that are life-saving or able to ameliorate quality of life. Every nation has their own rules as well as regulations surrounding the access and import of innovative drugs, and there are several different programmes as well as regulations set up for the same. These include the Named Patient Import, Expanded Access, Special Access Schemes/Programs, Compassionate Use Programme, and Early Access Programme, to name a few.

In the Named Patient Program (NPP), We (ikris Pharma Network) are providing medicines in every nook and cranny of India, such as Amritsar, Auli, Bangalore, Bareilly, Bhopal, Bhubaneshwar, Chennai, Chandigarh, Hosur, Hubli, Coimbatore, Cuttack, Faridabad, Gandhinagar, Ghaziabad, Goa, Gurgaon, Guwahati, Gwalior, Hyderabad, Indore, Jabalpur, Jaipur, Jammu, Jhansi, Jodhpur, Kanpur, Kochi, Kolkata, Kota, Lucknow, Ludhiana, Madurai, New Delhi, Mohali, Mumbai, Nasik, Navi Mumbai, Pahchkula, Patiala, Patna, Pondicherry, Pune, Puri, Ranchi, Noida, Secunderabad, Shimla, Srinagar, Thiruvananthapuram, Surat, Thane, Tirupura, Tirupati, Udaipur, Vadodara, Varanasi, Vellore, Vijayawada, Visakhapatnam, etc. in the following categories.

Oncology

Diabetes

Hepatitis

Hematology

Cardiology

Neuroscience

Immunology

Ophthalmology

Miscellaneous

We aid patients and physicians in importing hard-to-get medicinal products under their home country’s regulatory framework. We have created strategic partnerships with legitimate and authorized suppliers that deal in a wide range of medicines which come under the Named Patient Program (NPP). We impose specific care in dispatching all those medicines which require a proper cold chain.

Order Inquiry and Further Communication: Once we are initially contacted, our team works with the respective patient to make sure that they have first consulted with their treating physician to discuss the best course of treatment and have a valid prescription for the particular medication they need. From that juncture, our major role is to oversee the whole process. We manage each and every bit so the patient doesn't have to. This typically ranges from sourcing to shipping, to customs and delivery, as well as following up to ensure that everything was received in proper order. With assistance from our team, we help the patient and their treating physician every bit of the way. Throughout this process Indian Pharma Network helps patients by proactively providing them with deets on what to expect from starting to end. Respective patients also get precise updates on shipping, responses to all their queries and more answers on any other thing that may arise.

At Ikris Pharma Network (IPN), our specific goal is to offer customized assistance to each patient and treating physician so they don’t have to worry about how they will receive the particular medicine they need.

Our Clients: We specifically provide access to all critical medicines to patients across the world, including Asia, Latin America, Africa, Europe and other major countries. At Indian Pharma Network, every order stays confidential, ensuring the anonymity of the patient. We value your trust and are acutely aware of the critical nature of each and every shipment. To that end, we perform everything to honor the health as well as privacy of our clients.

How to Connect:In order to buy Named Patient Medicines from India, please write to us with your orders/prescriptions at info@indianpharmanetwork.in. You can also dial our 9310090915. Ikris Pharma international (IPN) will promptly acknowledge receipt of requests from treating physicians, within 24 to 48 hours of receiving the request for information.

[rklifecareincofficial]

Pharma manufacturing in Delhi is witnessing notable trends, with companies like RK Lifecare Inc. at the forefront. RK Lifecare Inc. is embracing advanced technologies, such as automation and data analytics, to enhance production efficiency and ensure quality control. Additionally, there's a growing emphasis on sustainable practices and regulatory compliance, reflecting the evolving landscape of pharmaceutical manufacturing in the region. Contact us today at +91 98112 25580 or for info@rklifecare.com inquiries or to schedule a consultation.

[gkpharmagreen]

Gk Pharma Green — What You Should Know About Herbal Extracts?

Nowadays herbal products rule every market. Pharma  trade is not exceptional here. As the herbal medicines proved their potency & benefits, there is a huge scope for pharma production houses in herbal medicines. These medicines produced with herbal extracts which is found from several life saving herbs. Then water, alcohol or some substances are mixed with it to make a herbal medicine. The pharma regulatory consultants helps in the entire process of extracting the herbal extracts. To know more login today.

https://gkpharmagreen.tumblr.com/post/637845562378600448/what-you-should-know-about-herbal-extracts

[royrishi699]

Gk Pharma Green — What You Should Know About Herbal Extracts?

Nowadays herbal products rule every market. Pharma  trade is not exceptional here. As the herbal medicines proved their potency & benefits, there is a huge scope for pharma production houses in herbal medicines. These medicines produced with herbal extracts which is found from several life saving herbs. Then water, alcohol or some substances are mixed with it to make a herbal medicine. The pharma regulatory consultants helps in the entire process of extracting the herbal extracts. To know more login today.

https://gkpharmagreen.tumblr.com/post/637845562378600448/what-you-should-know-about-herbal-extracts

[depioneeralliance]

Depioneer Expert Advice for Getting Pharma and Drug License in Delhi-NCR

Delhi: Today as we all know that Regulatory bodies related to drugs and medicines are tightening the norms for getting business licenses for Pharma Business. We here at Depioneer is having more than 2 Decades of Experience in Managing Hectic documentations for Pharma licensing whether Wholesale or Retail we deal in all types of Pharma License in India.

Get License for your Pharmacy Store with Depioneer Consultancy ,with Depioneer you can get your Drug application code in 7 days and License in 30 to 60 Days time. We have a Dedicated team of Pharma Licensing Experts sitting at our South Delhi Office , Always ready to give you Transparent and Genuine Information and Consultancy .

As we all know Licensing is mandatory for All Pharma and Cosmetics business in India.The law Drugs & Cosmetics Act, 1940 which is applicable to the whole of India. The Drug license is being given state wise, If you run your Business in Multiple states then you need multiple Licenses to run your Pharma Business. 

What Depioneer Offers:

1.Consultation to Check Eligibility

2.Documentation Finalization

3.Professional Application Drafting 

4.Application Filings

5.Government fees Payment and Coordination with Authority .

Following documents are required with application form :

Constitution of the firm (MOA/AOA)

Photo ID proof of proprietor/partner/director

Copy of Property paper (If owned property)

Copy of Rent agreement (If rented property)

Site Plan and key plan of the premises

Refrigerator invoice and details

Affidavit regarding compliance of MPD 2021 (if premises are located on DDA residential flat/ plot/ building)

Additional document for Retail Sale Registered Pharmacist

Proof of qualification i.e. final degree certificate/provisional certificate with mark sheets

Registration of Delhi Pharmacy Council

Appointment Letter and Bio-data

Additional document for Wholesale Licence Competent person

Proof of qualification i.e. final degree certificate/provisional certificate with mark sheets

Experience Certificate

Appointment Letter and Bio-data

For any problem related with Pharma License Enrollment, Please contact through this Link.:- "Contact Us"

You can Also Connect with Depioneer Group here: 

DEPIONEER ALLIANCE SERVICES

Call us: 7827261917, 7827260206, 011-46564790

mail us.: depioneerallianceservice@gmail.com

Visit us:http://depioneerenterprises.com/

member of phdcci number: 6179

[globalinstituteregulatoryaffairs]

Pharmacovigilance Job Opportunities In Top Companies

The pharmaceutical and healthcare sector has grown tremendously in the past few years. Out of which, pharmacovigilance is coming out as a viable option for students to build a stable career. The career growth and opportunities in Pharmacovigilance are immense. Pharmacovigilance aims to gather, understand, assess, and prevent adverse effects of a drug or medicinal product. This is done by various processes such as

1. Individual Case Safety Reports (ICSR).

2. Clinical Review of Safety Reports.

3. Cohort Event Monitoring.

4. Longitudinal Electronic Patient Reports.

5. Periodic Safety Update Reports (PSUR).

6. Spontaneous Recording.

7. Record Linkage.

8. Expedited Report.

A candidate in pharmacovigilance performs the following functions:

1. Reporting adverse events received from customers or healthcare bodies.

2. Reducing the risk of serious side effects.

3. Creating and reviewing serious adverse effects reports.

4. Performing safety audits.

Types of Companies Hiring in Pharmacovigilance

Pharmacovigilance provides a bright career option in terms of both growth and salary. The starting position in the domain is a pharmacovigilance associate or drug safety associate. The companies that hire pharmacovigilance professionals are:

1. Pharmaceutical companies.

2. Contract research organizations.

3. Biotechnology companies.

4. Dedicated pharmacovigilance centers.

5. Regulatory authorities.

6. Knowledge process outsourcing companies.

The above companies offer pharmacovigilance jobs for the following profiles:

1. Drug safety associate.

2. Pharmacovigilance associate.

3. Case processing expert.

4. Safety associate.

5. Clinical safety scientist.

6. Pharmacovigilance scientist.

Top 20 Pharmacovigilance Companies in India

1. Novartis

Novartis is headquartered in Basel, Switzerland and based out of Hyderabad in India. The company is also a CRO for pharmacovigilance and clinical data management.

2. Parexel

Parexel is one of the oldest and most popular CROs based out of Hyderabad in India. The company also operates in Chandigarh and Bangalore. It provides jobs in pharmacovigilance, regulatory affairs, clinical data management, medical writing, and so on.

Talk to us now for best suited

Pharmacovigilance course

3. Syneos Health

The INC Research and inVentiv Health merged to form a new company called Syneos Health. It is a well-known company from the US which is based out of Hyderabad, Pune and Delhi in India. It provides job opportunities in pharmacovigilance, clinical data management, medical writing, and so on.

4. Cognizant

Cognizant is headquartered in the US and is based out of Hyderabad, Mumbai, Pune, and Kolkata in India. It offers services in pharmacovigilance and clinical data management. Cognizant has numerous job opportunities for pharmacy graduates and postgraduates. Cognizant is one of the world's leading professional services firms, transforming clients' business, operating, and technology models for the digital world.

5. Accenture

Accenture is headquartered in Dublin, Ireland and based out of Bangalore, Chennai, and Hyderabad in India. It is the first big IT company to introduce pharmacovigilance services in India

6. Tata Consultancy Services (TCS)

TCS is a multinational company headquartered in Mumbai, India. It also operates in Pune, Nagpur, Indore, and Hyderabad. The company hires professionals for pharmacovigilance, clinical data management and regulatory affairs. TCS is increasing its Research and Development team for the Pharma Division and they are actively recruiting Pharmacovigilance Associates and Clinical Researchers.

7. Vigimedsafe

Vigimedsafe is headquartered in the US and based out of Hyderabad in India. It provides services in pharmacovigilance under various brackets such as aggregate reporting, signal detection, narrative writing, and so on. It is also a great company for freshers to learn and excel in the domain.

8. Makrocare

Makrocare is another old CRO based out of Hyderabad in India. The company offers opportunities in pharmacovigilance, clinical research, medical writing, regulatory affairs, and clinical data management.

9. Indegene

Indegene is a CRO headquartered in Bangalore, India. The company also finds its presence in the US, UK, China, and Japan. It offers job opportunities in pharmacovigilance, clinical data management, medical writing, and so on.

10. Freyr Solutions

Freyr Solutions is a leading company based out of Hyderabad in India. It provides end-to-end services in pharmacovigilance, regulatory affairs, and clinical data management.

11. iSafety

iSafety is another leading life science organization which provides opportunities in pharmacovigilance and clinical data management.

Apart from the above, the other companies hiring for pharmacovigilance are:

12. Dr Reddy’s Laboratories.

13. Aurobindo Pharma Limited.

14. BioClinica.

15. Inventive.

16. Genpact.

17. Quintiles.

18. HCL.

19. Novo Nordisk.

20. Kinapse.

21. Syngene.

Pharmacovigilance Job Locations in India

Pharmacovigilance services are provided by huge multinational giants based out of India with their services functional in the country. These companies have a global foothold in the pharmacovigilance domain and are based in metro cities in India. If you are interested in building a career in pharmacovigilance, you might have to consider moving to the following cities

1. Hyderabad.

2. Bangalore.

3. Mumbai

4. Pune

5. Chandigarh

6. Delhi

7. Chennai

To Sum It Up

Pharmacovigilance is a promising career for healthcare students. It offers a great salary along with stable career growth. The companies providing pharmacovigilance services are prominent all over the world with their headquarters in the US or Europe. In India, these companies are based out of metro and Tier-1 cities such as Bangalore, Hyderabad, Mumbai, and so on. If you wish to build a stable career in pharmacovigilance. For more information and to get trained click on Pharmacovigilance Course

[radis20unlife]

 pharma franchise in Delhi 

Radisun Lifesciences is the topmost WHO-GMP Certified Pharma third party manufacturing company in Republic of India. Our company is functioning in concert of the fastest-growing contract manufacturing drug company corporations in New Delhi (India). We are committed to provide high-quality health care medicinal products in the market. We manufacture and deliver the pharma goods at competitive market costs in India. We meet all the authorized regulatory regulations and work professionally to manage the quality standards of GMP Certified company in every division. Pharmaceutical tablets, dry suspension, capsules, ointments, liquid orals, creams and lotions, injectable, mouthwash are there in our pharmaceutical division. We tend to provide a large variety of medical formulations or molecules and consistent quality service. We tend to own well-equipped and advanced labs which permit us to supply high-quality health care formulations. Our skilled groups are able to contribute in each potential manner so as to serve the society. If you’re looking for Third Party producing drug company corporations in India, then Radisun Lifesciences, is the assorted group of consultants creating efforts in drug department to create new medications. These new inventions can be most advantageous in the heal

[indiaprdistribution1]

SARACA Solutions to triple headcount in India in two years with opening of a new office in Noida

The company has doubled its employee strength in the last 6 months with strong demand in medical devices, defense, and semiconductor industry segments.

Noida, December 21, 2021 – SARACA Solutions, a global IT consulting and engineering R&D services company, plans to triple its headcount in India in the next two years, anticipating strong growth in electric vehicles, UAV, medical devices, and artificial intelligence solutions.

The company expects demand to continue across major industry verticals, especially in digital engineering, and confident that the strong demand traction is likely to continue for the next few years, said Kuldeep Tyagi, founder and CEO.

SARACA is first company in product engineering services segment in India that focused early on complex regulations in medical, pharma and healthcare and developed strong capabilities. The company works for Fortune 500 clients and help them meet regulatory requirements in Europe, USA, Japan, and other major markets.

The company is ramping up recruitment at its Noida office and today inaugurated its new office which will be company’s new HQ. SARACA will add more than 500 engineers in the next two years to meet the demand in newer technologies like AI/ML, IoT, cloud, chip design and 5G, Tyagi said.

The new office was inaugurated by Dr. Ravindra Singh, Director, DPA, Defense Research and Development Association (DRDO), Delhi. Company employees, officials, and respected dignitaries were present in the opening ceremony.

The new hires will be a mix of both freshers and laterals. The company plans to hire local talent from engineering institutes in Delhi/NCR area. To bridge the industry-academia gap, SARACA has strong association with premier institutes including Krishna Institute of Engineering & Technology (KIET). SARACA caters primarily to the medical devices, pharma, automotive, semiconductor, consumer, telecom, and industrial sectors.

“The main objective behind expansion in Noida is to deepen our commitment to our strategic customers and this will also help in providing various employment opportunities for passionate engineering professionals. We have always worked towards doing challenging projects for our customers to differentiate ourselves and it has yielded in stronger customer relationships,” Tyagi said

The young, agile, and aggressive - SARACA is a 7-year-old company and has operations in Boston, USA, Bengaluru, Hyderabad, and Mumbai.

For more information, contact: Shilpa Negi, Marketing Manager shilpa.negi@saracasolutions.com

[ramshariraut]

Leptin Receptor  Market Research with Regional Growth Opportunity and Trends Forecast 2028

Global Leptin Receptor  Market, Geography (North America (United States, Canada and Mexico), South America (China, Japan, Korea, India and Southeast Asia), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Middle East and Africa (Saudi Arabia, Egypt, Nigeria and South Africa)) Industry Trends 2021-2028

<strong>Market Overview</strong> Illustrative analysis of critical sides such as resulting factors and competitive landscape are conveyed with the help of significant resources, such as charts, tables, graphs. The report executes a deep investigation of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also estimates the effect of different industrial sides on the Leptin Receptor   market divisions and regions. The research also divides the Leptin Receptor   Market on the basis of end-user, product type, application, and demography for the forecast period 2021–2028.

<strong> Request a sample Report of Leptin Receptor  Market @ <a href=https://www.statistifymarketresearch.com/reports/leptin-receptor-market/sample-request-80665>https://www.statistifymarketresearch.com/reports/leptin-receptor-market/sample-request-80665</a></strong>

<strong>Methodology</strong> The conditions influencing the market dynamics are considered and studied and examined to prepare an accurate report. In the report preparation process mainly two types of approaches are made- primary research approach and secondary research approach. In the primary research approach, both the supply and demand chain are interviewed where the supply chain consists of product, opinion leaders, etc. while the demand chain consists of industry experts. The secondary research approach involves various secondary sources like press releases, government agencies, and other commercial aspects of the market.

<strong>Report Summary</strong> Preparing a business report on Leptin Receptor    is the most important of all information-based writing because most of the business decisions are related to the organization after the evaluation of the situation as per the report. They are responsible for the documentation of the progress of the business and also serve several important purposes. The ability to write reports, quickly, and accurately is one of the key requirements of managers at every level. The reports allow them to convey vital information to subordinates and superiors. . The report on Leptin Receptor   prepared by us serves as a medium for understanding important business elements at the industrial and managerial level. Our report-making services entail flexible payment modes and budget-friendly rates.

<strong>Market segmentation</strong> The study splits the industry into a variety of sub-segments and thus represents the whole market. In addition, an estimate of the sales figures for the entire industry and its sub-segments are given in this report. It determines the variables that rapidly influence the market, including manufacturing methods and methodologies, channels for growth, and the product model. The report also outlines some of the biggest development opportunities, the introduction of the new products, market prediction, and forecasting, numerous economic factors that are key in deciding the Leptin Receptor  market pattern, buying decisions, and market attractiveness. The report would help stakeholders such as producers and distributors in finding and capturing high-potential markets. The research also addresses various environmental and regulatory critical factors.

<strong>Growth Mapping</strong> contains reason behind this report is to give a growth map with respect to the activities taken by key participants of the Leptin Receptor   market like item delivery, joint ventures,  influencing the Leptin Receptor   market and undertaking in general and furthermore influencing the business, import, fare, income and CAGR values. The report conveys the overall current realities about market definition, orders, applications, and commitment for the Leptin Receptor   market that are basic lead the market. The report moreover combines the overall organization profiles of the top players referred and also reflecting the drivers and limitations of the market with the support of SWOT analysis.

<strong>Top Listed Companies in the Leptin Receptor  Market Include</strong>

ConSynance Therapeutics Inc,Neurotez Inc,Jyant Technologies Inc,NeuroNano Pharma Inc,XL-protein GmbH,Novelion Therapeutics Inc

<strong>Reasons to buy this report:</strong> Learn about the Covid-19 Impact on Leptin Receptor   market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements. To gain insightful analyses of the research Industry and have a comprehensive understanding of the global Leptin Receptor   market and its commercial landscape. To understand the future outlook and prospects for the Leptin Receptor   market with Marketing & Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis).

<strong>Request for Customization @ <a href=https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=80665>https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=80665</a></strong>

<strong>Regional Analysis</strong> Different regions of the world such as North America, Latin America, the Asia-Pacific region, Europe, and India, China, and Australia have been analyzed on the basis of various parameters that would benefit the development of the market in the area. It contains the territorial as well as the wide level investigation of the market. It was observed that North America and Asia-pacific countries have shown impressive development opportunities in their region. Asia-Pacific nations due to such a large population in the area could be the prime region for developing a fully flourishing market full of consumer and low-cost labor. However, Europe, being a region of most developed countries seems to be lagging in the survey due to its climatic-driven guidelines which will affect the new settlement of the market.

<strong>Customization of the report: </strong> The customized report is provided by our consultancy at a reasonable price. We provide updated information according to the requirements of the customers in the market world.

<strong>Benefits:</strong> 1. Well updated information. 2. Statistical report provided. 3. Discount offer in customization. 4. Service at the global level. 5. Company research report provided.

<strong>Services:</strong> 1. Expert analysts at your service. 2. Service according to your needs 3. Clearance of your queries. 4. Whole day service 5. Well updated Report.

<strong>Frequently Asked Questions?</strong> Q1. What is the total market value of the Leptin Receptor  market report? Q2. What would be the forecast period in the Leptin Receptor  market report? Q3. What is the base year considered in the Leptin Receptor   market report? Q4. Which are the top companies hold the market share in the Leptin Receptor   market ? Q5. Which is expected to be the fastest growing segment in the Leptin Receptor   market? Q6. Which market holds the maximum market share of the Leptin Receptor   market ? Q7. How the company profile has been selected? Q8. What will be the market value of the Leptin Receptor  market in 2028?

<strong>Why do companies trust Statistify Market Research?</strong> Statistify Market Research rendering surveys, indemnity, data, facts, enumeration on worldwide as well as local variables is one of the notable market research and expert company based in India. It covers automobiles, medicine, and healthcare, food and beverage, semiconductor and electronics market, chemicals, ICT(Information and Communications Technology), packaging, consumer goods. The flourishing company has a certain specified quality which provides customer satisfaction with excellent commitment and is highly time-oriented thus bringing positive results for our customers.

<strong>Company Name - Statistify Market Research</strong> Office Address - 156, Sector 9 Vasundhra Aptts Rohini, New Delhi 110085 IN Telephone Numbers - (+44) 162-237-1047 (+44) 162-237-1047 Email ID - <a href="mailto:sales@statistifymarketresearch.com"><strong>sales@statistifymarketresearch.com</strong></a> Contact Us – <a href="https://www.statistifymarketresearch.com/contact-us/"><strong>https://www.statistifymarketresearch.com/contact-us/</strong></a>

[mahenderkhandelwal]

Bhushan Power and Steel Insolvency Professionals Mahender Khandelwal

I am Mahender Khandelwal is a registered insolvency and Chartered Accountant professional. Senior management and financial professional with wide experience spanning over 30 years in entire continuum of structuring, financing through debt and equity instruments. Management and turnaround of Special situations and Insolvency across wide spectrum of industries. Led Restructuring and Resolution of a large corporates (100+) across various sectors viz. Iron and Steel, Stainless Steel and utensils, System Packaging, Forging Industry, Pharma, Hotels, NBFC, Rice and Food Processing, Fertilizers, Biodiesel, Edible Oils, Biomass, Solar Panels, Power and Infrastructure, Textile, Education, Auto Component, Polymers, Electric Appliances, Plywood, Construction and Real Estate. Started BRS practice in BDO & PWC as Leader & Partner successfully resolved 20 plus cases in Insolvency under my leadership ranging fromm 200 crores to 50,000 crores.

 Prior to that I was running my Boutique Consultancy firm in the name of Varrenyam Consultants Pvt Ltd.

  MONITORING PROFESSIONAL

Bhushan Power and Steel Limited.

Jul 2017 – Mar 2021

3 years

 BPSL is the among first dirty dozen cases referred by lenders to insolvency. The company have a borrowing of more than 47000 crores from over 35 lenders. There has been an all-round growth and complete turnaround in the operations of the company since the commencement of CIRP. When RP took control over BPSL, capacity utilization was meagre 47% with production level of 82,000 MT per month and EBITDA loss. Due to combination of proactive CoC and decisions taken by the RP for enhancement of capacity utilization. During CIRP period production had increased to 200,000 MT and the company generated EBITDA of more than 4000 crores. Moreover, the company under the leadership of the RP/MP was able to reduce the statutory and worker liabilities besides improving working capital levels. The RP/MP further ensured smooth operations while managing 15,000 employees across 9 locations and provided increments to the employees. Some of the incomplete projects were completed by incurring additional CAPEX with COC approval. On the date of implementation there was working capital of more than 7500 crores in cash balance of around 2500 crores. During CIRP Period RP have handled enquiries/investigations from Regulatory Authorities i.e. SFIO, CBI, ED and GST for pre CIRP period including closing of draft forensic audit conducted during pre CIRP period including closing of draft forensic audit report conducted during pre CIRP period. Due to turnaround and enhanced operations, Resolution applicants improved their bid amount from initial12,000 crores to 19,800 crores and JSW successfully implemented the resolution plan and taken over control of BPSL. The Financial creditors have recovered around 42 percent of their dues in BPSL resolution.

  Corporate Insolvency Resolution Process

KSK MAHANADI POWER COMPANY LIMITED Oct 2019 – June 2020

Hyderabad Area, India, Power Plant at Bilaspur 3600MW

 KSK Mahanadi operates a coal-based power project with a nameplate capacity of 3600 MW. The company has 3 operational units and rest are under various stages of construction. After commencement of CIRP process, we are able to operate all 3 units generating highest load with 80% capacity utilization and PLF of about 76%. With existing operational and technical team, we have introduced various cost cutting programs to bring in efficiency in operations. In the ongoing COVID-19 lockdown, we were running the plant at full capacity and supplying power to distribution companies despite cash flow constraints. CIRP of KSK is substantially delayed as rail and water infrastructure of power plant are housed in separate subsidiary companies and lenders have filed a consolidated application in NCLT. Getting investors interest in standalone Power plant is a challenge due to unenviability of rail and water infrastructure.

 Resolution Professional

Prius Group of Entities

Apr 2019 – Present

New Delhi

 RP for 5 Commercial real estate companies of Ex Ranbaxy promoters namely Pawan Impex Pvt Ltd, SVIIT Software Pvt. Ltd, Payne Realtors Pvt Ltd, Prius Commercial Projects Pvt Ltd. and Sharan Hospitality Ltd.

  Financial  Creditors

  S. No.

Entity

Amount Admitted

Resolution  Amount

Percentage  Recovery

Resolution Applicant

 Stage of  Implementation

 1

Prius  Commercial Projects Private Limited

407.83

407.83

100.00%

Consortium  of Kotak Investment Advisors Limited, Minicon Insulated Wires LLP and Elita  Capital Advisors LLP

 implementation has been completed

successfully

 2

Sharan  Hospitality Private Limited

76.75

76.75

100.00%

Majestic Auto Limited

 Resolution Plan

approved,

implementation of plan

is still going on

 3

Payne  Realtors Private Limited

27.36

27.36

100.00%

City Gold Entertainment Ltd.

  implementation has

been

completed

successfully

4

Pawan  Impex Private Limited

194.85

130.00

67.00%

Consortium of DMI Alternative  Investment Fund - Special Opportunities Scheme, Fact Software Private Limited  and Yash Gupta

  Resolution Plan

approved,

implementation of plan

is still going on

 5

SVIIT  Software Private Limited

59.23

35.15

60.00%

Mr. Parmjit Gandhi

 Resolution Plan approved, implementation of plan

is

still going on

              Educomp Solutions Ltd.

May 2017 till date:

 Till date running the company as going concern and up to date in payment to employees, Statutory dues and operational expenses in spite of adverse situation due to covid 19. Resolution Plan of EBIX Singapore Pte. Ltd. was approved by the lenders and subsequently approved by NCLT. However, due to covid resolution applicant have filed application in NCLT/NCLAT for withdrawal which NCLAT not allowed. Resolution applicant filed in Supreme court, which is pending for final judgement.

   Partner and Leader Business Restructuring Services

PwC Professional Services LLP Full-time

Apr 2018 – Aug 2019

1 year

Gurgaon

 Joined as Partner & Leader of Business Recovery Services (BRS) practice at PwC India. PwC is among the top consultancy firm in India and a world leader in BRS & stressed asset resolution practices. As a BRS Leader, I was leading a team of 70 dedicated professionals for the overall development and growth of the vertical. I have overseen and guided various CIRP assignments under various RP’s including Uttam Value Steels, Uttam Galva Metallics, Era Infra & Engineering, Parabolic Drugs, Diamond Power Infrastructure Ltd, Videocon group companies, KSK Mahanadi, Sukam Power Systemsand PRIUS group of companies. During this stint, I have developed strong and credible relationships with, stressed assets funds, international fund houses, ARCs and NBFC.

   Partner & Leader- Business Restructuring

BDO India LLP Full-time

May 2017 – Apr 2018

1 year

New Delhi Area, India

 BDO India LLP is the India member firm of BDO International. BDO India offers strategic, operational, accounting, tax & regulatory advisory and assistance for both domestic and international organizations across a range of industries. As the leader and partner of BRS division, I was instrumental in establishing insolvency practice for BDO. Through persistent market development efforts, BDO was successfully awarded 3 out of first dirty dozen insolvency cases. These cases were Jyoti Structures, ABG Shipyards and Bhushan Power and Steel Ltd. BDO also won 3 cases in mid-market segment. I also developed a team of insolvency professionals, execution team for claim verification, process advisory, operation and maintenance, sectorial compliances, Balance sheet and cash flow monitoring. My team was the first one to develop system, procedures and SOP’s for insolvency practice. In the very first year of operations, we won more than Rs. 100 crore business.

    Managing Director

Varrenyam Consultants Private LimitedSelf-employed

May 2004 – May 2017

13 years  and From April 2021 to till date

New Delhi Area, India

 A boutique financial advisory services firm specializes in the field of financial restructuring of distressed companies, settlement of debts, and resources mobilization. During this period, I have advised more than 100 corporates on financial restructuring and settlements ranging from 200 crores to 25000 crores. My firm was leading advisor in the Corporate Debt Restructuring process (CDR) and was instrumental in strategy formulation, scheme preparation, financial modelling, valuation and techno economic studies. We were also involved in finding strategic investor/buyers for some of the companies where post restructuring plan required change of management.

We also organised funding for distressed assets through ARC, special situation funds, NBFC’s.

Post implementation of CIRP assignments I have restarted my above Boutique firm.

    General Manager Finance

ROLLATAINERS LTD 

Apr 2000 – Apr 2004

4 years

Faridabad, Haryana and Delhi

 As finance head, my job profile included Treasury Management, funds control including collections and disbursements and supervision of banking transactions. I was directly reporting to the President, Executive Director and Board of Directors comprising top Professionals. I was instrumental in implementing Financial and Operational Restructuring. Financial restructuring involved Rephasement of repayments and lowering of interest rates in first phase, creating vehicle for Venture fund investment and saving the company from BIFR. As a member of Board presentation to board on various restructuring options, Strategy formation and approvals of board on various cost cutting and restructuring options including shutting down. I also involved in strategy formation and approvals of board on various cost cutting and restructuring options including shutting down of loss-making businesses. Redesigning of MIS Systems and assisting top management on various financial strategies. Consolidation and Centralization of Finance, Accounts and Purchase function. Business valuation, financial modeling, Audit Finalization – Statutory, Internal, Tax, Stock, Concurrent and due diligences.

   Senior Manager-Finance &Accouts

Modi Rubbers Ltd 

May 1997 – Mar 2000

2 yrs 11 months

Delhi Area, India

 Part of Modicorp (ultimate holding company of B. K. Modi group companies), I was responsible for managing funds, control, overall supervision of accounts department of 13 companies in layers of holding and subsidiary structure. I was also involved in Tax Planning, finalization of Accounts and interaction with Statutory, Internal, Tax Auditors and Auditors for valuation and Due Diligence. I also supported group financial controller for credit rating in respect of US$ 50 Million ECB. Liaison with banks, financial institutions and taxation authorities.

   Sr. Manager-Finance

SARDA PLYWOOD INDUSTRIES LTD

Mar 1992 – Mar 1997

5 yrs 1 mo

Delhi, India

 As a part new project division, worked on project evaluation and viability study of various projects and participated in launching of new project from grass root level to concept paper for management, Joint Venture partners, and term lending institutions, venture capital funds, banks and state level institutions. I was also responsible for arrangement of export credit limits from banks and export documentation. Overall supervision of Accounts department, balance sheet finalization and other related activities.

[gkpharmagreen]

Pharmaceutical Consultants at Geekay Pharmagreen

The best pharma regulatory consultants in Delhi come from Geekay Pharmagreen to assist your pharma business. They have the expertise to deal with pharma regulatory matters for the last 35 years. For qms and regulatory related difficulties, you can depend on them. Visit their website to know more about this now.

https://youtu.be/7gZDGdDSA8w

[bbcbreakingnews]

Govt fillip for API, medical device production

NEW DELHI: Giving a major boost to local production of drug API and high end medical devices, the government on Monday released guidelines of four incentive schemes for the development of bulk drug and medical device parks across the country. The production linked incentive schemes were approved by the Cabinet in March and are worth over Rs 10,000 crore. The schemes are aimed at reducing India’s dependence on China for raw materials to produce crucial antibiotics, anti-HIV drugs, vitamins, and cardio medicines, and in production of medical devices, for which India is crucially dependent upon imports. “In line with the vision of Prime Minister Narendra Modi, the schemes have been conceptualised for making India Atma Nirbhar in pharma sector,” Union minister of chemicals and fertilizers D V Sadananda Gowda said. The scheme primarily deals with production of 53 critical active pharmaceutical ingredients (APIs) or key starting materials (KSMs). The coronavirus crisis has exposed the weakness in global supply chains and posed threat to the health security of the country, Gowda said. While proactive steps by the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority ensured steady supply of medicines, and prevented any shortage even during the lockdown, it was felt that domestic capabilities in production of APIs and medical devices have to be ramped up in order to eliminate any risks to the health security, he added. “The details of the schemes have been drawn up meticulously after having in depth consultations with stakeholders including industries and state governments. The selection of their location will be based on objective criteria, and in spirit of competitive federalism,” Gowda said. Similarly, eligible manufacturers will be selected for the PLI scheme on the basis of marks obtained in the evaluation criteria as per the guidelines, he added. “Supported by both central and state governments, these parks will be based on plug and play model with prior regulatory approvals, state of art infrastructure, excellent connectivity, affordable land, competitive utility charges, and strong R & D ecosystem and so on,” Gowda said. “I am sure that these schemes will elicit good response from interested companies. These parks will be able to attract significant investment as well as latest technology. Once operational, in about two to three years, these parks will generate thousands of direct and indirect jobs, reduce import dependency and, make India a global pharmaceutical hub,” Gowda said. The idea is also to cement India’s position as global drug supplier. As already known, in spite of various odds, India supplied critical medicines such as hydroxychloroquine and paracetamol to number of countries, he added.

The post Govt fillip for API, medical device production appeared first on BBC BREAKING NEWS.

from WordPress https://bbcbreakingnews.com/govt-fillip-for-api-medical-device-production/

[workfromhom]

India seeks new regulator for non-personal data

India should set up a data regulator to oversee how companies collect, process, store, monetize and even destroy non-personal data (or data that has been anonymized), a panel tasked by New Delhi has recommended in a draft report.

The eight-person panel said that companies such as Google, Facebook, Amazon, and Uber have benefited from a combination of “first mover advantage,” “sizable network effect” and “enormous data” that they have collected over the years.

This dominance has “left many new entrants and startups being squeezed and faced with significant entry barriers,” said the draft report, which has been made available to industry players for consultation before it is submitted to the nation’s IT ministry next month.

New Delhi, which appointed the aforementioned committee last year, has in recent years moved to better understand and control how technology companies make use of data and devise new guidelines for several sectors including e-commerce.

India has emerged as battleground for global giants such as Google, Facebook, Amazon, and ByteDance that are looking to court hundreds of millions of first-time internet users in Asia’s third-largest economy.

Last month, New Delhi banned 59 apps and services developed by Chinese firms citing security and privacy concerns. On Monday, Google announced it plans to invest $10 billion in India to help accelerate the adoption of digital services.

In the draft report, obtained by TechCrunch and embedded below, the panel said that a data authority that provides centralized regulations for all non-personal data exchanges is required to closely evaluate and oversee the aforementioned aspects.

“Market transactions and market forces on their own will not bring about the maximum social and economic benefits from data for the society. Appropriate institutional and regulatory structures are essential for a thriving data economy and a well-functioning data society,” the report said.

The proposed regulator will have “integration” with “raw data pipes” of tech companies, and will be able to exercise its legal power to make data sharing requests.

The draft report also recommends that companies provide their users with metadata of information they are collecting or processing from them so that “users may identify opportunities for combining data from multiple data businesses and/or governments to develop innovative solutions, products and services.”

“Every data business must declare what they do and what data they collect, process and use, in which manner, and for what purposes. This is similar to disclosures required by pharma industry and in food products,” the draft report recommends.

( function() { var func = function() { var iframe = document.getElementById('wpcom-iframe-92a899a72f2efda423dd5f910f72eb22') if ( iframe ) { iframe.onload = function() { iframe.contentWindow.postMessage( { 'msg_type': 'poll_size', 'frame_id': 'wpcom-iframe-92a899a72f2efda423dd5f910f72eb22' }, "https:\/\/tcprotectedembed.com" ); } } // Autosize iframe var funcSizeResponse = function( e ) { var origin = document.createElement( 'a' ); origin.href = e.origin; // Verify message origin if ( 'tcprotectedembed.com' !== origin.host ) return; // Verify message is in a format we expect if ( 'object' !== typeof e.data || undefined === e.data.msg_type ) return; switch ( e.data.msg_type ) { case 'poll_size:response': var iframe = document.getElementById( e.data._request.frame_id ); if ( iframe && '' === iframe.width ) iframe.width = '100%'; if ( iframe && '' === iframe.height ) iframe.height = parseInt( e.data.height ); return; default: return; } } if ( 'function' === typeof window.addEventListener ) { window.addEventListener( 'message', funcSizeResponse, false ); } else if ( 'function' === typeof window.attachEvent ) { window.attachEvent( 'onmessage', funcSizeResponse ); } } if (document.readyState === 'complete') { func.apply(); /* compat for infinite scroll */ } else if ( document.addEventListener ) { document.addEventListener( 'DOMContentLoaded', func, false ); } else if ( document.attachEvent ) { document.attachEvent( 'onreadystatechange', func ); } } )();

from Facebook – TechCrunch https://ift.tt/2WeimkU via IFTTT

[un-enfant-immature]

India seeks new regulator for non-personal data

India should set up a data regulator to oversee how companies collect, process, store, monetize and even destroy non-personal data (or data that has been anonymized), a panel tasked by New Delhi has recommended in a draft report.

The eight-person panel said that companies such as Google, Facebook, Amazon, and Uber have benefited from a combination of “first mover advantage,” “sizable network effect” and “enormous data” that they have collected over the years.

This dominance has “left many new entrants and startups being squeezed and faced with significant entry barriers,” said the draft report, which has been made available to industry players for consultation before it is submitted to the nation’s IT ministry next month.

New Delhi, which appointed the aforementioned committee last year, has in recent years moved to better understand and control how technology companies make use of data and devise new guidelines for several sectors including e-commerce.

India has emerged as battleground for global giants such as Google, Facebook, Amazon, and ByteDance that are looking to court hundreds of millions of first-time internet users in Asia’s third-largest economy.

Last month, New Delhi banned 59 apps and services developed by Chinese firms citing security and privacy concerns. On Monday, Google announced it plans to invest $10 billion in India to help accelerate the adoption of digital services.

In the draft report, obtained by TechCrunch and embedded below, the panel said that a data authority that provides centralized regulations for all non-personal data exchanges is required to closely evaluate and oversee the aforementioned aspects.

“Market transactions and market forces on their own will not bring about the maximum social and economic benefits from data for the society. Appropriate institutional and regulatory structures are essential for a thriving data economy and a well-functioning data society,” the report said.

The proposed regulator will have “integration” with “raw data pipes” of tech companies, and will be able to exercise its legal power to make data sharing requests.

The draft report also recommends that companies provide their users with metadata of information they are collecting or processing from them so that “users may identify opportunities for combining data from multiple data businesses and/or governments to develop innovative solutions, products and services.”

“Every data business must declare what they do and what data they collect, process and use, in which manner, and for what purposes. This is similar to disclosures required by pharma industry and in food products,” the draft report recommends.

( function() { var func = function() { var iframe = document.getElementById('wpcom-iframe-92a899a72f2efda423dd5f910f72eb22') if ( iframe ) { iframe.onload = function() { iframe.contentWindow.postMessage( { 'msg_type': 'poll_size', 'frame_id': 'wpcom-iframe-92a899a72f2efda423dd5f910f72eb22' }, "https:\/\/tcprotectedembed.com" ); } } // Autosize iframe var funcSizeResponse = function( e ) { var origin = document.createElement( 'a' ); origin.href = e.origin; // Verify message origin if ( 'tcprotectedembed.com' !== origin.host ) return; // Verify message is in a format we expect if ( 'object' !== typeof e.data || undefined === e.data.msg_type ) return; switch ( e.data.msg_type ) { case 'poll_size:response': var iframe = document.getElementById( e.data._request.frame_id ); if ( iframe && '' === iframe.width ) iframe.width = '100%'; if ( iframe && '' === iframe.height ) iframe.height = parseInt( e.data.height ); return; default: return; } } if ( 'function' === typeof window.addEventListener ) { window.addEventListener( 'message', funcSizeResponse, false ); } else if ( 'function' === typeof window.attachEvent ) { window.attachEvent( 'onmessage', funcSizeResponse ); } } if (document.readyState === 'complete') { func.apply(); /* compat for infinite scroll */ } else if ( document.addEventListener ) { document.addEventListener( 'DOMContentLoaded', func, false ); } else if ( document.attachEvent ) { document.attachEvent( 'onreadystatechange', func ); } } )();

[ramshariraut]

"Global Weight Reduction Medicine  Market 2021-2028 | Latest COVID19 Impact Analysis | Know About Brand Players: Roche,Lunan Pharmaceutical Group Corporation,Sandoz(Novartis),GSK group,National Company For Pharmaceutical Industry,Teva,Hisun,Hexal AG,STADA-VN J.V.Co., Ltd,Zein Pharmaceutical,Taj Pharmaceuticals Ltd,China Zhongshan Pharm,Kabir Life Sciences & Research,Dm Pharma "

Global Weight Reduction Medicine  Market, Geography (North America (United States, Canada and Mexico), South America (China, Japan, Korea, India and Southeast Asia), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Middle East and Africa (Saudi Arabia, Egypt, Nigeria and South Africa)) Industry Trends 2021-2028

<strong>Market overview</strong> This market report on Weight Reduction Medicine   can help the companies to make crucial business plans on production techniques, raw materials procurement, and to increase the industry chain cycle of the market globally. The case study report on Weight Reduction Medicine   is a brief history and a detailed assessment of the Weight Reduction Medicine   market 2021 including key company profiles, and overall competitive scenario, key market trends, upcoming technologies, industry drivers, challenges, regulatory policies.

<strong> Request a sample Report of Weight Reduction Medicine  Market @ <a href=https://www.statistifymarketresearch.com/reports/weight-reduction-medicine-market/sample-request-80874>https://www.statistifymarketresearch.com/reports/weight-reduction-medicine-market/sample-request-80874</a></strong>

<strong>Methodology</strong> The research work involved the usage of both primary and secondary data sources. The research methods involved the study of many points affecting the industry, including government guidelines, market surroundings, combative landscape, past data. Primary and Secondary research are the two methods that are used for the survey purpose. The primary sources consist of having interviews with many industry experts, suppliers, and other specialists. The secondary sources consist of an analysis of empirical data from press releases, government-designed websites, yearly reports of the companies, and other related documents. Other fields of the examination are modern shifting in the market, technological invention, upcoming technologies, and the technical enhancement in related industries, market risks, opportunities, hindering, and risks in the operating market. The Data acquirement phase involves gathering and merging market information and data related with the help of various sources and research processes. Structured databases such as D&B Hoover and Bloomberg are used which helps to recognize the competitive environment of top market players along with profile details.

<strong>Regional Analysis</strong> Any type of report on Weight Reduction Medicine   is a highly valuable and important tool for any business association regardless of the scale on which it operates in the sector. It provides a source to track and examine the performance and overall condition of the business while also identifying fields that has the scope for improvement for the better functioning of the organization. A well-prepared business report also holds great value as it suggests preventive measures that need to be done to avoid the business fails to meet the desired targets and thus helps to recover from the adversities. An annual report on Weight Reduction Medicine   prepared in the company is an effective tool for providing employees, investors, and other clients with a complete picture of their business.

<strong>Customization of the Report: </strong> The customized report is provided by our consultancy at a reasonable price. We provide updated information according to the requirements of the customers in the market world.

<strong>Top Listed Companies in the Weight Reduction Medicine  Market Include</strong>

Roche,Lunan Pharmaceutical Group Corporation,Sandoz(Novartis),GSK group,National Company For Pharmaceutical Industry,Teva,Hisun,Hexal AG,STADA-VN J.V.Co., Ltd,Zein Pharmaceutical,Taj Pharmaceuticals Ltd,China Zhongshan Pharm,Kabir Life Sciences & Research,Dm Pharma

<strong>Reasons to buy this Report:</strong> It helps in understanding the major key product segments. This report throws on Weight Reduction Medicine   light on the dynamics of the market such as drivers, restraints, trends, and opportunities. It offers the regional analysis of Weight Reduction Medicine   Market along with business profiles of several stakeholders in the research market. It offers massive data about trending factors that will influence the progress of the Weight Reduction Medicine   Market. It offers an in-depth analysis of the changing competitive scenario in the Weight Reduction Medicine   market of the research industry.

<strong>Request for Customization @ <a href=https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=80874>https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=80874</a></strong>

<strong>Benefits:</strong> 1. Well updated information. 2. Statistical report provided. 3. Discount offer in customization. 4. Service at the global level. 5. Company research report provided.

<strong>Services:</strong> 1. Expert analysts at your service. 2. Service according to your needs 3. Clearance of your queries. 4. Whole day service 5. Well updated Report.

<strong>Frequently Asked Questions?</strong> Q1. What is the total market value of the Weight Reduction Medicine  market report? Q2. What would be the forecast period in the Weight Reduction Medicine  market report? Q3. What is the base year considered in the Weight Reduction Medicine   market report? Q4. Which are the top companies hold the market share in the Weight Reduction Medicine   market ? Q5. Which is expected to be the fastest growing segment in the Weight Reduction Medicine   market? Q6. Which market holds the maximum market share of the Weight Reduction Medicine   market ? Q7. How the company profile has been selected? Q8. What will be the market value of the Weight Reduction Medicine  market in 2028?

<strong>Full Report Summary of Weight Reduction Medicine  Market @ <a href=https://www.statistifymarketresearch.com/weight-reduction-medicine-market>https://www.statistifymarketresearch.com/weight-reduction-medicine-market</a></strong>

<strong>About Statistify Market Research</strong> Statistify Market Research is a market research organization that endeavors to furnish all clients with the most ideal help and suggestions. Our research is exceptionally intended for your associations working in all areas and assist them with investigating viable development techniques and proposals. We don't hold fast to a uniform rule. We comprehend that your organization has explicit research necessities, and we endeavor to comprehend the subtleties of your individual research needs so we can give you concentrated research administrations.

<strong>Company Name - Statistify Market Research</strong> Office Address - 156, Sector 9 Vasundhra Aptts Rohini, New Delhi 110085 IN Telephone Numbers - (+44) 162-237-1047 (+44) 162-237-1047 Email ID - <a href="mailto:sales@statistifymarketresearch.com"><strong>sales@statistifymarketresearch.com</strong></a> Contact Us – <a href="https://www.statistifymarketresearch.com/contact-us/"><strong>https://www.statistifymarketresearch.com/contact-us/</strong></a>

[mahenderkhandelwal]

About Mahender Kumar Khandelwal Insolvency Professional

I am Mahender Kumar Khandelwal is a professional registered insolvency and Chartered Accountant professional. Senior management and financial professional with wide experience spanning over 30 years in the entire continuum of structuring, financing through debt and equity instruments. Management and turnaround of Special situations and Insolvency across a wide spectrum of industries.

Led Restructuring and Resolution of large corporates (100+) across various sectors viz. Iron and Steel, Stainless Steel and utensils, System Packaging, Forging Industry, Pharma, Hotels, NBFC, Rice and Food Processing, Fertilizers, Biodiesel, Edible Oils, Biomass, Solar Panels, Power and Infrastructure, Textile, Education, Auto Component, Polymers, Electric Appliances, Plywood, Construction and Real Estate.

Started BRS practice in BDO & PWC as Leader & Partner successfully resolved 20 plus cases in Insolvency under my leadership ranging from 200 crores to 50,000 crores. Before that, I was running my Boutique Consultancy firm in the name of Varrenyam Consultants Pvt Ltd.

MONITORING PROFESSIONAL

Bhushan Power and Steel Limited. Jul 2017 – Mar 2021 3 years

BPSL is the among first dirty dozen cases referred by lenders to insolvency. The company have a borrowing of more than 47000 crores from over 35 lenders. There has been an all-around growth and complete turnaround in the operations of the company since the commencement of CIRP.

When RP took control over BPSL, capacity utilization was meagre 47% with a production level of 82,000 MT per month and EBITDA loss. Due to a combination of proactive CoC and decisions taken by the RP for enhancement of capacity utilization.

During CIRP period production had increased to 200,000 MT and the company generated EBITDA of more than 4000 crores. Moreover, the company under the leadership of the RP/MP was able to reduce the statutory and worker liabilities besides improving working capital levels. The RP/MP further ensured smooth operations while managing 15,000 employees across 9 locations and provided increments to the employees. Some of the incomplete projects were completed by incurring additional CAPEX with COC approval. On the date of implementation, there was a working capital of more than 7500 crores in a cash balance of around 2500 crores.

During CIRP Period RP have handled enquiries/investigations from Regulatory Authorities i.e. SFIO, CBI, ED and GST for pre CIRP period including the closing of a draft forensic audit conducted during pre CIRP period including the closing of draft forensic audit report conducted during pre CIRP period.

Due to turnaround and enhanced operations, Resolution applicants improved their bid amount from initial12,000 crores to 19,800 crores and JSW successfully implemented the resolution plan and taken over control of BPSL. The Financial creditors have recovered around 42 percent of their dues in BPSL resolution.

Corporate Insolvency Resolution Process KSK MAHANADI POWER COMPANY LIMITED Oct 2019 – June 2020 Hyderabad Area, India, Power Plant at Bilaspur 3600MW

KSK Mahanadi operates a coal-based power project with a nameplate capacity of 3600 MW. The company has 3 operational units and the rest are under various stages of construction. After commencement of CIRP process, we can operate all 3 units generating the highest load with 80% capacity utilization and PLF of about 76%.

With the existing operational and technical team, we have introduced various cost-cutting programs to bring in efficiency in operations. In the ongoing COVID-19 lockdown, we were running the plant at full capacity and supplying power to distribution companies despite cash flow constraints.

CIRP of KSK is substantially delayed as rail and water infrastructure of the power plant are housed in separate subsidiary companies and lenders have filed a consolidated application in NCLT. Getting investors interest in standalone Power plants is a challenge due to the unenviability of rail and water infrastructure.

Educomp Solutions Ltd. September 2017 till date:

Till date running the company as going concerned and up to date in payment to employees, Statutory dues and operational expenses despite adverse situation due to covid 19. The Resolution Plan of EBIX Singapore was approved by the lenders and subsequently approved by NCLT. However, due to covid resolution applicants have filed an application in NCLT/NCLAT for withdrawal which NCLAT is not allowed. Resolution applicant filed in Supreme court, which is pending for final judgement.

Partner and Leader Business Restructuring Services PwC Professional Services LLP Full-time Apr 2018 – Aug 2019 1 year Gurgaon

Joined as Partner & Leader of Business Recovery Services (BRS) practise at PwC India. PwC is among the top consultancy firm in India and a world leader in BRS & stressed asset resolution practices.

As a BRS Leader, I was leading a team of 70 dedicated professionals for the overall development and growth of the vertical. I have overseen and guided various CIRP assignments under various RP’s including Uttam Value Steels, Uttam Galva Metallics, Era Infra & Engineering, Parabolic Drugs, Diamond Power Infrastructure Ltd, Videocon group companies, KSK Mahanadi, Sukam Power Systems and PRIUS group of companies.

During this stint, I have developed strong and credible relationships with, stressed assets funds, international fund houses, ARCs and NBFC.

Partner & Leader- Business Restructuring BDO India LLP Full-time May 2017 – Apr 2018 1 year New Delhi Area, India

BDO India LLP is the India member firm of BDO International. BDO India offers strategic, operational, accounting, tax & regulatory advisory and assistance for both domestic and international organizations across a range of industries.

As the leader and partner of BRS division, I was instrumental in establishing insolvency practice for BDO. Through persistent market development efforts, BDO was successfully awarded 3 out of the first dirty dozen insolvency cases. These cases were Jyoti Structures, ABG Shipyards and Bhushan Power and Steel Ltd. BDO also won 3 cases in the mid-market segment. I also developed a team of insolvency professionals, an execution team for claim verification, process advisory, operation and maintenance, sectorial compliances, Balance sheet and cash flow monitoring. My team was the first one to develop systems, procedures and SOP’s for insolvency practice. In the very first year of operations, we won more than Rs. 100 crore businesses.

Managing Director Varrenyam Consultants Private LimitedSelf-employed May 2004 – May 2017 13 years and From April 2021 to till date New Delhi Area, India

A boutique financial advisory services firm specializes in the field of financial restructuring of distressed companies, settlement of debts, and resources mobilization. During this period, I have advised more than 100 corporates on financial restructuring and settlements ranging from 200 crores to 25000 crores.

My firm was a leading advisor in the Corporate Debt Restructuring process (CDR) and was instrumental in strategy formulation, scheme preparation, financial modelling, valuation and techno-economic studies. We were also involved in finding strategic investors/buyers for some of the companies where the post-restructuring plan required a change of management. We also organised funding for distressed assets through ARC, special situation funds, NBFC’s. Post-implementation of CIRP assignments I have restarted my above Boutique firm.

General Manager Finance ROLLATAINERS LTD Apr 2000 – Apr 2004 4 years Faridabad, Haryana and Delhi

As finance head, my job profile included Treasury Management, funds control including collections and disbursements and supervision of banking transactions. I was directly reporting to the President, Executive Director and Board of Directors comprising top Professionals.

I was instrumental in implementing Financial and Operational Restructuring. The financial restructuring involved Rephasement of repayments and lowering of interest rates in the first phase, creating a vehicle for Venture fund investment and saving the company from BIFR. As a member of Board presentation to board on various restructuring options, Strategy formation and approvals of the board on various cost-cutting and restructuring options including shutting down.

I was also involved in strategy formation and approvals of the board on various cost-cutting and restructuring options including shutting down loss-making businesses. Redesigning of MIS Systems and assisting top management on various financial strategies. Consolidation and Centralization of Finance, Accounts and Purchase function. Business valuation, financial modelling, Audit Finalization – Statutory, Internal, Tax, Stock, Concurrent and due diligence.

Senior Manager-Finance & Accounts Modi Rubbers Ltd May 1997 – Mar 2000 2 yrs 11 months Delhi Area, India

Part of Modicorp (ultimate holding company of B. K. Modi group companies), I was responsible for managing funds, control, overall supervision of accounts department of 13 companies in layers of holding and subsidiary structure.

I was also involved in Tax Planning, finalization of Accounts and interaction with Statutory, Internal, Tax Auditors and Auditors for valuation and Due Diligence. I also supported the group financial controller for credit rating in respect of US$ 50 Million ECB. Liaison with banks, financial institutions and taxation authorities.

Sr. Manager-Finance SARDA PLYWOOD INDUSTRIES LTD Mar 1992 – Mar 1997 5 yrs 1 mo Delhi, India

As a part of new project division, worked on project evaluation and viability study of various projects and participated in the launching of a new project from grass root level to a concept paper for management, Joint Venture Partners, and term lending institutions, venture capital funds, banks and state-level institutions.

I was also responsible for the arrangement of export credit limits from banks and export documentation. Overall supervision of Accounts department, balance sheet finalization and other related activities.